Astex In Cell-Cycle Inhibitor Deal With Novartis For Up To $520M

LONDON - Astex Therapeutics Ltd. landed a $520 million deal with Novartis AG for three cell-cycle inhibitors, the largest advertised figure for any deal involving a UK biotech to date, and bringing the total potential value of licenses granted by Astex in the past year to more than $1 billion. (BioWorld Today)